MacroGenics Inc. (MGNX)

[PAC]

Mgnx 27 halt wow. And i shorted, sheww

[rsconcept]

TIME TO SHORT

[rsconcept]

IT'S GOING TO DROP LIKE A HOT POTATO

[Actualfactual]

This is just getting stupid now over 25

[ClayTrader]

false.... a FREAK on STEROIDS...

[TheFinalCD]

MGNX green candle FREAK

[TheFinalCD]

3M shares short https://www.finviz.com/quote.ashx?t=mgnx&ty=c&ta=1&p=d

[TFMG]

$MGNX 14% Afterhours Breakout on positive phase 3 results

Afterhours Macrogenics Inc has announced Positive Results from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer. This has resulted in a 15% jump in price on high volume , we will looking for continuation tomorrow, this could be a flyer.

[ClayTrader]

* * $MGNX Video Chart 02-06-2019 * *

Link to Video - click here to watch the technical chart video

[Schabblestone]

last 30min,this thing will CLIMB

[crudeoil24]

Ben derr, done dat!

[Emptyhead]

Im expecting the same ;)

[crudeoil24]

38M share trading float. May run into 30's or low 40's today. Let's see where the whales, tutes, hedge funds, and Ivy League endowment funds take MGNX.

[crudeoil24]

It will be interesting how the tutes play this one out today. MGNX

[TheFinalCD]

they..... just loaded all they way down to 20.64 now printing 23's

MGNX

[TheFinalCD]

from 29 to 20's they are selling this like they know something

OFFERING coming?

hmmmmm


very shady trading going on here

[TheFinalCD]

21,738 trade @ $21= $456,288.00

crazy blocks going thru

looks pretty manipulated & shady

[TheFinalCD]

wow some bodies buying a crap load of MGNX @ 21.50 area

obviously some one is selling a crap load too

might be the freakin 89% in Institutions

https://finviz.com/quote.ashx?t=MGNX&ty=c&ta=1&p=d

[ClayTrader]

* * $MGNX Video Chart 12-10-18 * *

Link to Video - click here to watch the technical chart video

[DataScience]

Phase 1b/2 Study of Margetuximab in Combination with Pembrolizumab Presented at 2018 ASCO Gastrointestinal Cancers SymposiumBack to Press Releases
Share Story
30 minutes ago, 2:00PM ET 1/18/2018 Globe Newswire
Chemotherapy-free, immunotherapeutic combination evaluated
32% Overall response rate in second-line gastric cancer patients
Well tolerated in dose escalation and expansion cohorts
Rockville, MD, Jan. 18, 2018 (GLOBE NEWSWIRE) --

MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced presentation of data from its clinical trial of margetuximab plus pembrolizumab for patients with advanced gastric and gastroesophageal junction (GEJ) cancers in a poster session at the 2018 ASCO Gastrointestinal Cancers Symposium in San Francisco, California. The poster was titled "Phase 1b/2 Study of Margetuximab Plus Pembrolizumab in Advanced HER2+ Gastroesophageal Junction or Gastric Adenocarcinoma."

This Phase 1b/2 open-label, dose escalation study evaluates margetuximab, an Fc-optimized anti-HER2 monoclonal antibody, in combination with pembrolizumab, an anti-PD-1 antibody. The trial seeks to characterize the safety, tolerability, maximum tolerated dose, and preliminary anti-tumor activity of this combination. Enrolled patients had relapsed or refractory advanced HER2+ gastric or GEJ cancer with disease progression after or resistance to treatment with trastuzumab plus chemotherapy. Study patients were enrolled irrespective of PD-L1 expression status.

A Phase 1b dose escalation segment of the study tested dose levels of 10 and 15 mg/kg margetuximab in combination with a flat dose of 200 mg pembrolizumab every three weeks. After completion of dose escalation, Phase 2 dose expansion cohorts were enrolled, including a 30 patient cohort in North America and a 30 patient cohort in Asia. Sixty dose expansion patients received margetuximab at 15 mg/kg and 200 mg of pembrolizumab every three weeks.

Acceptable tolerability was observed in the safety population of 67 patients. Grade 3 or higher treatment-related adverse events (TRAE) occurred in 11.9% of patients. The most common TRAE of any grade was fatigue (14.9%).

As of the December 4, 2017 data cut-off date, responses were evaluable from 51 patients, including 25 with gastric and 26 with GEJ cancer. The Overall Response Rate (ORR) was higher in patients with gastric vs. GEJ cancer (32% vs. 4%). ORR across all patients in the study was 18% (six confirmed and three unconfirmed patients). Similarly, Disease Control Rate (including partial responses and stable disease) was higher in patients with gastric vs. GEJ cancer (72% vs. 38%). Median progression-free survival was also higher in patients with gastric vs. GEJ cancer (5.5 vs. 1.4 months).

"We are encouraged by the tolerability and anti-tumor activity of this novel, chemotherapy-free regimen combining margetuximab with an anti-PD-1 mAb for treatment of patients with advanced HER2+ gastric cancer," said Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics. "We are expanding the study by enrolling 25 additional gastric cancer patients and will continue to evaluate biomarkers, including HER2 and PD-L1 expression, to determine the patients who are most likely to benefit from margetuximab plus anti-PD-1 therapy. We expect to provide an update on these data later this year and define future development options for this regimen in the context of existing standard-of-care."

The poster presented at the 2018 ASCO Gastrointestinal Cancers Symposium is available for download from the Events & Presentations page on MacroGenics' website at http://ir.macrogenics.com/events.cfm.

About Margetuximab

Margetuximab is an Fc-optimized monoclonal antibody that targets the human epidermal growth factor receptor 2, or HER2 oncoprotein. HER2 is expressed by tumor cells in breast, gastric, gastroesophageal, bladder and other forms of solid tumor cancers, making it a key marker for biologic therapy. The Phase 1b/2 study of margetuximab in gastric and gastroesophageal cancer incorporates pembrolizumab, which is provided by Merck & Co., under a previously announced arrangement. MacroGenics is also studying margetuximab as a potential treatment for metastatic breast cancer in a Phase 3 study called SOPHIA, for which an interim futility analysis is expected to be completed by the end of January 2018.

About MacroGenics, Inc.

MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases. The company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics, the MacroGenics logo, and DART are trademarks or registered trademarks of MacroGenics, Inc.

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company's strategy, future operations, clinical development of the Company's therapeutic candidates, milestone or opt-in payments from the Company's collaborators, the Company's anticipated milestones and future expectations and plans and prospects for the Company and other statements containing the words "subject to", "believe", "anticipate", "plan", "expect", "intend", "estimate", "project", "may", "will", "should", "would", "could", "can", the negatives thereof, variations thereon and similar expressions, or by discussions of strategy constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation and enrollment of future clinical trials, expectations of expanding ongoing clinical trials, availability and timing of data from ongoing clinical trials, expectations for regulatory approvals, other matters that could affect the availability or commercial potential of the Company's product candidates and other risks described in the Company's filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views only as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so, except as may be required by law. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

###

ti?nf=NzA4MTA0OCMyMDM1Mjk4IzIwMDg5NTc=

CONTACTS:
Jim Karrels, Senior Vice President, CFO
MacroGenics, Inc.
1-301-251-5172, [e-mail]

Karen Sharma, Senior Vice President
MacDougall Biomedical Communications
1-781-235-3060, [e-mail]

[wiltonio]

Boxer Capital, LLC has filed a new 13G, reporting 5.5% ownership in $MGNX - https://fintel.io/so/us/mgnx and https://fintel.io/i/boxer-capital-llc

[stocktrademan]

$MGNX DD Notes ~ http://www.ddnotesmaker.com/MGNX

bullish
good volume
double bottom

$MGNX recent news/filings

## source: finance.yahoo.com

Fri, 21 Nov 2014 23:02:56 GMT ~ Nasdaq stocks posting largest percentage decreases

[AP] - A look at the 10 biggest percentage decliners on Nasdaq at the close of trading: Ohr Pharmaceutical fell 32.1 percent to $7.74. Web.com Inc. fell 19.9 percent to $27.70. Aemetis Inc. fell 12.5 percent ...

read full: http://sg.finance.yahoo.com/news/nasdaq-stocks-posting-largest-percentage-220242625--finance.html
*********************************************************

Thu, 20 Nov 2014 13:55:14 GMT ~ 4 Biotech Catalyst Stocks to Buy With 60% to 100% Upside Potential


read full: http://247wallst.com/healthcare-business/2014/11/20/4-biotech-catalyst-stocks-to-buy-with-60-to-100-upside-potential/
*********************************************************

Wed, 19 Nov 2014 18:04:27 GMT ~ MACROGENICS INC Financials


read full: http://finance.yahoo.com/q/is?s=mgnx
*********************************************************

Wed, 19 Nov 2014 11:09:16 GMT ~ MacroGenics (MGNX) in Focus: Stock Rises 7% in Session


read full: http://finance.yahoo.com/news/macrogenics-mgnx-focus-stock-rises-110916953.html
*********************************************************

Wed, 12 Nov 2014 21:36:39 GMT ~ MacroGenics to Present at the Stifel 2014 Healthcare Conference

[at noodls] - November 11, 2014 -- Four oncology molecules in clinical development; on track to have six by 2015 year-end -- Margetuximab Phase 3 study in metastatic breast cancer to initiate in 2015 -- MGD007 (gpA33 ...

read full: http://www.noodls.com/view/FCF456CAE5F047EE22BB13BA2724F3470581591C
*********************************************************


$MGNX charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com


$MGNX company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/MGNX/company-info
Ticker: $MGNX
OTC Market Place: Not Available
CIK code: not found
Company name: MacroGenics, Inc.
Incorporated In:


$MGNX share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available
$MGNX extra dd links

Company name: MacroGenics, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/MGNX/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/MGNX/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=MGNX+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=MGNX+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=MGNX+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/MGNX/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/MGNX/news - http://finance.yahoo.com/q/h?s=MGNX+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/MGNX/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/MGNX/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/MGNX/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/MGNX/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/MGNX/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/MGNX/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/MGNX/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/MGNX/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=MGNX+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/MGNX
DTCC (dtcc.com): http://search2.dtcc.com/?q=MacroGenics%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=MacroGenics%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=MacroGenics%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/MGNX/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/MGNX
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/MGNX/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/MGNX/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/MGNX/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/MGNX/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/MGNX/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/MGNX/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/MGNX/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=MGNX&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=MGNX
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/MGNX/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=MGNX+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=MGNX+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=MGNX
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=MGNX
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=MGNX+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/MGNX/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=MGNX+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/MGNX.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=MGNX
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/MGNX/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/MGNX/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/MGNX/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/MGNX/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/MGNX
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/MGNX
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/MGNX:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=MGNX
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=MGNX



$MGNX DD Notes ~ http://www.ddnotesmaker.com/MGNX

[imtheking]

Potential Buy Out
http://seekingalpha.com/article/2330365-gileads-pipeline-requires-macrogenics-immunooncology-platform-m-and-a

[imtheking]

Pipeline Review
http://seekingalpha.com/article/2458795-macrogenics-a-late-stage-pipeline-review

[imtheking]

Corporate Update
http://finance.yahoo.com/news/macrogenics-provides-corporate-progress-second-200500609.html

[phryne]

Takeda collaboration is some minor verification of technology.

[surf1944]

1:17PM MacroGenics announced presentation of pre-clinical data on DART Molecule Targeting CD123-Positive Leukemic Stem Cells (MGNX) 26.00 -0.01 : The pre-clinical study investigated the ability of a DART, constructed from MacroGenics' proprietary anti-CD3 antibody and an antibody to CD123, to redirect T cells against CD123-positive AML blasts. Investigators demonstrated that the CD3 x CD123 DART, MGD006, binds to both human CD3 and CD123 to mediate target-effector cell aggregation, T-cell activation and proliferation. MGD006 induced a dose-dependent reduction of primary AML blast survival in vitro and in vivo. Notably, a short course of treatment with MGD006 in mice engrafted with an AML patient sample (at an initial T cell : blast ratio of 1:111) induced a near complete elimination ( > 97%) of AML blasts from the peripheral blood and significant clearing from the spleen and bone marrow at 6 weeks post AML cell infusion. The results of this study provide a strong rationale for the clinical development of the MGD006 as a novel molecule for the treatment of patients with AML.

[Gixene]

New board.